Status:
COMPLETED
A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)
Lead Sponsor:
Eisai Korea Inc.
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-89 years
Brief Summary
This study is an observational study conducted prospectively under routine clinical setting for 1 year with about 700 patients diagnosed as Alzheimer's disease who will be treated by donepezil (Aricep...
Detailed Description
Participation in this study places no additional visit schedule, which will be determined by the investigator's judgment based on the disease progression of each subject. Investigators educate subject...
Eligibility Criteria
Inclusion
- Greater than or equal to 50 years old and less than 90 years old
- Diagnosed as probable AD based on NINCDS-ADRDA
- Patients who have been recently prescribed with donepezil (Aricept) as monotherapy
- Patients and caregivers who signed the written informed consent from for use of personal and medical information
- Patients with caregivers who can visit the institution together
Exclusion
- 1\) Patients who have taken Memantine or Acetylcholinesterase (AChE) inhibitor prior to participating in the study
Key Trial Info
Start Date :
July 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
532 Patients enrolled
Trial Details
Trial ID
NCT02262975
Start Date
July 1 2014
End Date
August 1 2016
Last Update
December 28 2016
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, China
2
Gangwon, China
3
Hong Kong, China
4
Nanjing, China